Antares Pharma, Inc. (ATRS) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
100 PRINCETON SOUTH EWING, NJ 08628 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 3841 - Surgical and Medical Instruments and Apparatus (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | 9/30/2020 Q3 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 57,365 | 45,126 | 55,652 | 53,137 | 52,169 | ||||
| Cash and cash equivalents | 57,365 | 45,126 | 55,652 | 53,137 | 50,172 | ||||
| Short-term investments | 1,997 | ||||||||
| Receivables | 54,471 | 54,224 | 42,940 | 42,221 | 42,507 | ||||
| Inventory, net of allowances, customer advances and progress billings | 16,493 | 18,644 | 19,614 | 18,216 | 19,809 | ||||
| Inventory | 16,493 | 18,644 | 19,614 | 18,216 | 19,809 | ||||
| Contract with customer, asset, after allowance for credit loss | 2,942 | 5,725 | 10,960 | 8,140 | 8,784 | ||||
| Other undisclosed current assets | 2,162 | 4,244 | 4,352 | 4,877 | 1,851 | ||||
| Total current assets: | 133,433 | 127,963 | 133,518 | 126,591 | 125,120 | ||||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 3,892 | 4,014 | 4,285 | 4,621 | 4,881 | ||||
| Property, plant and equipment | 25,832 | 25,590 | 24,276 | 24,020 | 22,547 | ||||
| Intangible assets, net (including goodwill) | 7,072 | 7,280 | 7,488 | 8,788 | |||||
| Goodwill | 1,095 | ||||||||
| Intangible assets, net (excluding goodwill) | 7,072 | 7,280 | 7,488 | 7,693 | |||||
| Deferred income tax assets | 43,987 | 45,249 | 46,392 | 46,982 | |||||
| Other noncurrent assets | 2,523 | 2,523 | 2,498 | 1,529 | 3,026 | ||||
| Total noncurrent assets: | 83,306 | 84,656 | 84,939 | 85,940 | 30,454 | ||||
| TOTAL ASSETS: | 216,739 | 212,619 | 218,457 | 212,531 | 155,574 | ||||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 44,895 | 45,452 | 43,137 | 41,829 | 40,862 | ||||
| Accounts payable | 12,885 | 15,797 | 16,764 | 16,194 | 18,016 | ||||
| Accrued liabilities | 32,010 | 29,655 | 26,373 | 25,635 | 22,846 | ||||
| Deferred revenue | 3,804 | 2,675 | 1,570 | 3,943 | 3,277 | ||||
| Debt | 2,918 | 22,813 | 26,260 | 16,230 | 6,415 | ||||
| Other undisclosed current liabilities | 917 | 1,035 | 1,177 | 1,203 | |||||
| Total current liabilities: | 52,534 | 71,975 | 72,144 | 63,205 | 50,554 | ||||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 23,014 | 7,890 | 19,362 | 29,485 | 39,298 | ||||
| Long-term debt, excluding current maturities | 18,401 | 3,338 | 14,765 | 24,669 | 34,358 | ||||
| Liabilities, other than long-term debt | 363 | 726 | 726 | 726 | 481 | ||||
| Deferred revenue | |||||||||
| Other liabilities | 363 | 726 | 726 | 726 | 481 | ||||
| Operating lease, liability | 4,613 | 4,552 | 4,597 | 4,816 | 4,940 | ||||
| Total noncurrent liabilities: | 23,377 | 8,616 | 20,088 | 30,211 | 39,779 | ||||
| Total liabilities: | 75,911 | 80,591 | 92,232 | 93,416 | 90,333 | ||||
| Equity | |||||||||
| Equity, attributable to parent, including: | 140,828 | 132,028 | 126,225 | 119,115 | 65,241 | ||||
| Additional paid in capital | 348,834 | 345,431 | 344,063 | 340,756 | 338,277 | ||||
| Accumulated other comprehensive loss | (686) | (686) | (693) | (683) | (691) | ||||
| Accumulated deficit | (209,020) | (214,413) | (218,833) | (222,626) | (274,012) | ||||
| Other undisclosed equity, attributable to parent | 1,700 | 1,696 | 1,688 | 1,668 | 1,667 | ||||
| Total equity: | 140,828 | 132,028 | 126,225 | 119,115 | 65,241 | ||||
| TOTAL LIABILITIES AND EQUITY: | 216,739 | 212,619 | 218,457 | 212,531 | 155,574 | ||||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | 9/30/2020 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | (135,252) | 48,191 | 44,978 | 42,083 | 44,133 | 40,003 | ||
| Cost of revenue | (19,037) | (16,517) | ||||||
| Cost of goods and services sold | (16,517) | |||||||
| Gross profit: | 48,191 | 44,978 | 42,083 | 25,096 | 23,486 | |||
| Operating expenses | (40,226) | (21,751) | (20,247) | (18,998) | (17,636) | |||
| Other undisclosed operating loss | (16,440) | (16,445) | ||||||
| Operating income (loss): | 7,965 | 6,787 | 5,391 | 6,098 | 5,850 | |||
| Nonoperating expense | (744) | (1,224) | (1,008) | (3,802) | (72) | |||
| Other nonoperating income (expense) | 6 | (89) | (46) | (72) | ||||
| Interest and debt expense | (750) | (1,135) | (962) | (977) | (782) | |||
| Income (loss) from continuing operations before equity method investments, income taxes: | 6,471 | 4,428 | 3,421 | 1,319 | 4,996 | |||
| Other undisclosed income from continuing operations before income taxes | 750 | 1,135 | 962 | 3,787 | ||||
| Income (loss) from continuing operations before income taxes: | 7,221 | 5,563 | 4,383 | 5,106 | 4,996 | |||
| Income tax expense (benefit) | (1,828) | (1,143) | (590) | |||||
| Other undisclosed income from continuing operations | 46,280 | |||||||
| Income (loss) from continuing operations: | 5,393 | 4,420 | 3,793 | 51,386 | 4,996 | |||
| Income (loss) before gain (loss) on sale of properties: | ✕ | 5,393 | 4,420 | 3,793 | 51,386 | 4,996 | ||
| Net income (loss) available to common stockholders, diluted: | 5,393 | 4,420 | 3,793 | 51,386 | 4,996 | |||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | 9/30/2020 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | 5,393 | 4,420 | 3,793 | 51,386 | 4,996 | |||
| Other comprehensive income (loss) | 7 | (10) | 8 | 5 | ||||
| Comprehensive income (loss), net of tax, attributable to parent: | 5,393 | 4,427 | 3,783 | 51,394 | 5,001 | |||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.